Energy Transfer and Sunoco donate $2 million to support pediatric cancer research at MD Anderson

HOUSTON ― The University of Texas MD Anderson Cancer Center today announced a $2 million donation from Dallas-based Energy Transfer as a result of its 2024 workplace giving campaign. Funds raised through employee donations and corporate matching support pediatric cancer research at MD Anderson.

“The generous contributions from more than 1,200 Energy Transfer and Sunoco employees across the country is truly remarkable,” said Richard Gorlick, M.D., division head and chair of Pediatrics at MD Anderson. “Through the dedicated support of these committed employees, we can fund important clinical trials that make a significant difference in the lives of pediatric cancer patients now and in the future.”

Since 2014, Energy Transfer and Sunoco employees have led fundraising efforts that have donated more than $17 million to MD Anderson. The annual campaign includes contributions from corporate funds and more than $1 million from the Energy Transfer/Sunoco Foundation. All funds will support pediatric cancer research at MD Anderson Children’s Cancer Hospital.

“Energy Transfer and Sunoco employees are proud to continue their support of MD Anderson and its mission to eliminate cancer through their exceptional research and treatment efforts,” said Chris Curia, chief human resources officer for Energy Transfer. “We continue to be inspired by the truly remarkable advances their research is bringing to the treatment of pediatric cancers and the differences being made in the lives of children and their families.”

In October, representatives from MD Anderson Children’s Cancer Hospital visited Energy Transfer’s headquarters in Dallas, Texas. The team met with Energy Transfer senior leaders, including Curia and Kelcy Warren, executive chairman, and Mackie McCrea, co-chief executive officer.

Gorlick shared many of the research breakthroughs made possible through Energy Transfer’s generosity over the past decade, including menin inhibitor research, which is particularly impactful for pediatric patients facing leukemia and other blood diseases.